Company: ARVN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001655759-25-000139
Chunk: 84

Company: ARVINAS, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 84
---
6)(2.8)Prepaid expenses and other assets(3.1)(6.0)Collaboration contract asset— (3.0)Accounts payable and accrued liabilities(17.6)(13.9)Operating lease liability(1.0)(1.0)Deferred revenue(211.3)50.0 Net cash used in operating activities(184.3)(47.2)Cash flows from investing activities:Purchases of marketable securities(237.6)(440.4)Maturities of marketable securities437.5 326.4 Purchases of property, equipment and leasehold improvements(1.6)(0.8)Proceeds from disposal of property, equipment and leaseholds improvements— 0.1 Net cash provided by (used in) investing activities198.3 (114.7)Cash flows from financing activities:Repayments of long-term debt(0.1)(0.3)Proceeds from exercise of stock options and issuance of ESPP shares0.5 5.3 Net cash provided by financing activities0.4 5.0 Net increase (decrease) in cash, cash equivalents and restricted cash14.4 (156.9)Cash, cash equivalents and restricted cash, beginning of the period100.5 317.2 Cash, cash equivalents and restricted cash, end of the period$114.9 $160.3 Supplemental disclosure of cash flow information:Cash paid for taxes$— $1.5 

See accompanying notes to the condensed consolidated financial statements

5

ARVINAS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (unaudited)

1. Nature of Business and Basis of Presentation

Arvinas, Inc. and its subsidiaries (“Arvinas” or the "Company”) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP